Skip to main content
. Author manuscript; available in PMC: 2021 Jul 7.
Published in final edited form as: Support Care Cancer. 2020 Jan 2;28(9):4163–4172. doi: 10.1007/s00520-019-05254-6

Table 1.

Demographic and clinical characteristics of interview participants.

Characteristic Participants
n=34
Age [Mean (SD), range] 56.9 (8.8), 39–71
Race [n (%)]
 Caucasian 31 (91.2)
 African American 1 (2.9)
 Other 2 (5.9)
Diagnosis of diabetes [n (%)] 1 (2.9)
Chemotherapy setting [n (%)]
 Adjuvant 25 (73.5)
 Neoadjuvant 9 (26.5)
Receipt 12 doses paclitaxel [n (%)]a 22 (64.7)
a

Four women decreased (range between doses 7 and 12) or delayed (range between doses 3 and 11) paclitaxel dose; nine women discontinued treatment before completing their 12 scheduled doses (range between doses 6 and 10).